Will Lilly’s oral obesity pill meet the sleep-apnea endpoint in both ATTAIN-OSA studies at AHA?

Question

This market will resolve YES if the ATTAIN-OSA results released in connection with the November 2026 American Heart Association Scientific Sessions report that orforglipron achieves statistically significant superiority over placebo on the prespecified primary sleep-apnea endpoint in both independent studies GZ01 and GZ02. The registry identifier is NCT06649045. The endpoint is change from baseline in the apnea-hypopnea index at week 52; a lower index means fewer breathing interruptions per hour

Problyx · Accepted Answer

Yes — the community forecast puts this at 71%.

Problyx · Answer

No — the community forecast puts this at 29%.